Cancer Letters

Cancer Letters

Volume 367, Issue 2, 28 October 2015, Pages 113-121
Cancer Letters

Mini-review
The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer

https://doi.org/10.1016/j.canlet.2015.07.026Get rights and content

Highlights

  • Summary of preclinical and clinical studies on IGF axis inhibition in the treatment of prostate cancer.

  • We summarize preliminary results from ongoing studies and discuss limitations and side effects of the substances used.

  • We address the role of the IGF axis in the biomarkers setting including IGF-binding proteins and genetic variants.

Abstract

Prostate cancer (PCa) is the most common cancer and the second leading cause of cancer death in males. In recent years, several new targeting agents have been introduced for the treatment of advanced stages of the disease. However, development of resistance limits the efficacy of new drugs and there is a further need to develop additional novel treatment approaches. One of the most investigated targets in cancer research is the insulin-like growth factor (IGF) axis, whose receptors are overexpressed in several cancer entities including PCa. In preclinical studies in PCa, targeting of the IGF axis receptors showed promising anti-tumor effects. Currently available data on clinical studies do not meet the expectations for this new treatment approach. In this review we provide a summary of preclinical and clinical studies on the IGF axis in PCa including treatment with monoclonal antibodies and tyrosine kinase inhibitors. Moreover, we summarize preliminary results from ongoing studies and discuss limitations and side effects of the substances used. We also address the role of the IGF axis in the biomarkers setting including IGF-binding proteins and genetic variants.

Introduction

Prostate cancer (PCa) is the most common male cancer and the third cause of cancer death among men in European countries [1]. PCa is a heterogeneous disease, ranging from slow-growing indolent tumors to rapidly progressing and highly aggressive carcinomas associated with significant morbidity and mortality. Targeting the androgen receptor (AR) signaling pathway is the current standard treatment for hormone-naïve PCa. After two to three years, however, AR signaling is reactivated leading to castration resistant PCa (CRPC) [2], [3]. Until two years ago, chemotherapy with docetaxel was the standard treatment for this stage of disease. However, next-generation AR targeting agents such as abiraterone acetate or enzalutamide have been developed and are now routinely used in the clinical setting [4], [5], [6]. In addition carbazitaxel, a next-generation taxane, has been approved for CRPC after docetaxel relapse [7]. In 2013 the U.S. Food and Drug Administration (FDA) approved radium-223 chloride (radium-223) for the treatment of metastatic CRPC in patients whose metastases are limited to the bones [8]. Table 1 provides an overview of drugs currently approved for treatment of CRPC [4], [7], [8], [9], [10], [11], [12], [13].

Despite this progress in therapy, not all patients respond to current therapies and in the majority of cases development of therapy resistance is inevitable. There remains therefore a need for new agents selectively targeting anti-cancer pathways. Several new drugs are currently in advanced phases of clinical testing and it is hoped that some may be added to the therapeutic armamentarium in the near future. The insulin-like growth factor (IGF) axis is one of the most investigated targets in cancer and mediates critical physiological processes, including cellular growth, cell differentiation, apoptosis, development as well as glucose and lipid metabolism [14], [15], [16], [17], [18]. Moreover, the IGF axis plays a fundamental role in regulating embryonic growth [19]. IGFs also exert growth stimulating and pro-survival effects on tumor cells and have been shown to mediate carcinogenesis, angiogenesis, malignant cell proliferation and metastatic growth of a variety of tumors [20], [21], [22].

To date, more than 100 agents have been developed that target the receptors of the IGF axis and many are currently being evaluated in preclinical and clinical studies. The present review provides an overview of IGF targeting agents, their mechanisms of action, advantages and disadvantages as well as the current status of their application in the clinical setting of PCa.

Section snippets

Insulin-like growth factor (IGF) axis

The IGF axis is a multicomponent network composed of three ligands, IGF1, IGF2 and insulin, and the receptors IGF1 receptor (IGF1R), IGF2 receptor (IGF2R) and insulin receptor (INSR) [23], [24] (Fig. 1). The biological functions of IGF1 and IGF2 are predominantly mediated by IGF1R, a tyrosine kinase transmembrane receptor that binds IGF1 with higher affinity than IGF2. The IGF2R is a mannose 6-phosphate receptor implicated in targeting lysosomal enzymes. It binds IGF2 with higher affinity than

Preclinical studies demonstrating the role of the IGF axis in prostate cancer

Preclinical studies have demonstrated that the IGF axis modulates the development and progression of PCa. IGF1 signaling is elevated in PCa compared to benign prostate tissue and plays a role in tumor progression [36], [37], [38], [39]. In addition, IGF receptors have been shown to be overexpressed in several cancer entities, including PCa [40], [41], [42], [43], [44]. Data obtained from mouse cells with a disrupted IGF1R gene suggest that this receptor is a prerequisite for cells to undergo

Interaction of the IGF axis with the AR pathway

The AR is a key promoter of PCa growth, tumor progression, therapy and drug resistance. In former studies the AR has been shown to upregulate IGF1R expression via an active AR binding site in the IGF1R gene promoter [96]. Pandini et al. reported that androgens induce a selective up-regulation of IGF1R in PCa cells thereby increasing cell proliferation and invasiveness in response to IGF1 [97]. Moreover, re-expression of wild-type but not mutant AR in an AR-negative PCa cell line significantly

IGF axis components as prostate cancer biomarkers

In the past years a large number of population-based studies have been performed to investigate the suitability of IGF axis components as biomarkers in PCa detection, monitoring and selection of therapy. The conflicting results of these studies are still a matter of debate and are summarized below.

Conclusion

The first results from clinical trials of IGF-based therapies for PCa have been disappointing in comparison to the high promise these agents demonstrated in pre-clinical studies. However, the final results of many of these clinical studies encompassing quite different clinico-pathological settings are yet to be published. A comprehensive understanding of the function of the IGF axis as a whole, as well as redundant and non-redundant functions of IGF and INSR receptors, is mandatory to

Funding

COMET Center Oncotyrol (Project 2.1.4), the Autonomous Province of Bolzano – South Tyrol (Grant 37/40.3), the Austrian Cancer Foundation Tyrol, and the Austrian Science Fund (FWF, V216-B13 and W1101).

Conflict of interest

All authors have no conflict of interest to declare.

References (117)

  • M. Fassnacht et al.

    Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

    Lancet Oncol

    (2015)
  • G.V. Scagliotti et al.

    Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer

    Ann. Oncol

    (2015)
  • A.L. Cohn et al.

    A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

    Ann. Oncol

    (2013)
  • D.W. Cooke et al.

    Analysis of the human type I insulin-like growth factor receptor promoter region

    Biochem. Biophys. Res. Commun

    (1991)
  • H. Schayek et al.

    Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells

    Mol. Cell. Endocrinol

    (2010)
  • R. Siegel et al.

    Cancer statistics, 2013

    CA Cancer J. Clin

    (2013)
  • E.G. Bluemn et al.

    The androgen/androgen receptor axis in prostate cancer

    Curr. Opin. Oncol

    (2012)
  • J.L. Mohler et al.

    The androgen axis in recurrent prostate cancer

    Clin. Cancer Res

    (2004)
  • C.J. Ryan et al.

    Abiraterone in metastatic prostate cancer without previous chemotherapy

    N. Engl. J. Med

    (2013)
  • J.S. De Bono et al.

    Abiraterone and increased survival in metastatic prostate cancer

    N. Engl. J. Med

    (2011)
  • J. Hoffman-Censits et al.

    Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer

    Clin. Cancer Res

    (2013)
  • C. Parker et al.

    Alpha emitter radium-223 and survival in metastatic prostate cancer

    N. Engl. J. Med

    (2013)
  • I.F. Tannock et al.

    Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

    N. Engl. J. Med

    (2004)
  • T.M. Beer et al.

    Enzalutamide in metastatic prostate cancer before chemotherapy

    N. Engl. J. Med

    (2014)
  • P.W. Kantoff et al.

    Sipuleucel-T immunotherapy for castration-resistant prostate cancer

    N. Engl. J. Med

    (2010)
  • H.I. Scher et al.

    Increased survival with enzalutamide in prostate cancer after chemotherapy

    N. Engl. J. Med

    (2012)
  • D. Le Roith

    The insulin-like growth factor system

    Exp. Diabesity Res

    (2003)
  • A. Belfiore et al.

    Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease

    Endocr. Rev

    (2009)
  • A. Giacca et al.

    Differential effects of IGF-I and insulin on glucoregulation and fat metabolism in depancreatized dogs

    Diabetes

    (1990)
  • G. Rodriguez-Tarduchy et al.

    Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells

    J. Immunol

    (1992)
  • B.W. Sutherland et al.

    Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium

    Cancer Res

    (2008)
  • M. Pollak

    Insulin and insulin-like growth factor signalling in neoplasia

    Nat. Rev. Cancer

    (2008)
  • I. Heidegger et al.

    Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis

    Oncotarget

    (2014)
  • I. Heidegger et al.

    Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells

    Endocrinology

    (2012)
  • A.A. Samani et al.

    The role of the IGF system in cancer growth and metastasis: overview and recent insights

    Endocr. Rev

    (2007)
  • E. Foulstone et al.

    Insulin-like growth factor ligands, receptors, and binding proteins in cancer

    J. Pathol

    (2005)
  • J. Riedemann et al.

    IGF1R signalling and its inhibition

    Endocr. Relat. Cancer

    (2006)
  • P. Massoner et al.

    Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer

    Br. J. Cancer

    (2010)
  • A. Belfiore

    The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer

    Curr. Pharm. Des

    (2007)
  • S.M. Firth et al.

    Cellular actions of the insulin-like growth factor binding proteins

    Endocr. Rev

    (2002)
  • V. Hwa et al.

    The insulin-like growth factor-binding protein (IGFBP) superfamily

    Endocr. Rev

    (1999)
  • J.S. De Bono et al.

    Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor

    Clin. Cancer Res

    (2007)
  • J. DiGiovanni et al.

    Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice

    Proc. Natl. Acad. Sci. U.S.A.

    (2000)
  • S.L. Krueckl et al.

    Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model

    Cancer Res

    (2004)
  • T. Nickerson et al.

    In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR)

    Cancer Res

    (2001)
  • G.O. Hellawell et al.

    Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease

    Cancer Res

    (2002)
  • U. Bergmann et al.

    Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles

    Cancer Res

    (1995)
  • C. Fottner et al.

    Overexpression of the insulin-like growth factor I receptor in human pheochromocytomas

    J. Mol. Endocrinol

    (2006)
  • G. Pandini et al.

    Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling

    Clin. Cancer Res

    (1999)
  • M.M. Weber et al.

    Overexpression of the insulin-like growth factor I receptor in human colon carcinomas

    Cancer

    (2002)
  • Cited by (50)

    • IGF2 induces CD133 expression in esophageal cancer cells to promote cancer stemness

      2018, Cancer Letters
      Citation Excerpt :

      However, we are still far from fully understanding the molecular mechanisms that drive CSC maintenance in ESCC. Insulin-like growth factors (IGF) play important roles in many tumor proliferation, growth, differentiation, and angiogenesis, and are therefore regarded as promising targets in cancer therapy [10,11]. Although insulin-like growth factors 1 (IGF1) and insulin-like growth factor 2 (IGF2) share about 70% homology in amino acid sequence, they each have their distinct functions.

    • IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway

      2018, Neoplasia (United States)
      Citation Excerpt :

      IGF1R is often overexpressed in PCa, and it associates with carcinogenesis, proliferation, and migration of PCa [8,9]. Targeting the IGF axis receptors showed promising antitumor effects in preclinical studies of PCa treatment [10]. MicroRNAs (miRNAs) are conserved small noncoding RNAs that act as posttranscriptional regulators of gene expression.

    • Molecular Biology of Human Cancers

      2023, Molecular Biology of Human Cancers
    View all citing articles on Scopus
    View full text